Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

NCT05907291 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Adrenal Hyperplasia
Classic Congenital Adrenal Hyperplasia

Interventions

DRUG: atumelnant (CRN04894)

Sponsor

Crinetics Pharmaceuticals Inc.